October 3, 2024 07:29 AM EDTUpdated 07:43 AM
Pharma

Eli Lil­ly re­solves short­age for tirzepatide, po­ten­tial­ly end­ing com­pounder­s' run

Ayisha Sharma

News Reporter

Eli Lil­ly’s block­buster GLP-1 drug tirzepatide is fi­nal­ly back on track in the US af­ter two years of in­ter­mit­tent short­ages dri­ven by high de­mand, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Septer­na files for Nas­daq list­ing as biotech IPOs come to life

BioN­Tech opens the hood on its AI am­bi­tions, and they're not just for mR­NA

Res­o­lu­tion rais­es $85M to test macrophage ther­a­pies in end-stage liv­er dis­ease

EMA looks to make its drug ap­proval process­es more ef­fi­cient

Ex­clu­sive: Af­ter dis­cov­er­ing an­tibi­otics with AI, a 31-year-old first-time CEO rais­es $17M to fight ag­ing

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times